ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Timing of conception after methotrexate and subsequent pregnancy outcomes: A retrospective cohort study.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMethotrexate is widely used to treat ectopic pregnancy (EP). Concerns about its teratogenicity have led to uncertainty regarding the optimal interval before attempting conception. Guidelines recommend a 3-month washout period, while the manufacturer advises 6 months. Evidence on the safety of early conception is limited. We aimed to evaluate whether conception within 1-3 months after methotrexate treatment for EP is as safe as conception after longer intervals.
methodsWe conducted a retrospective cohort study of women treated with 30-150 mg methotrexate for ectopic pregnancy in Clalit Health Services hospitals (2010-2021). Subsequent pregnancies were categorized by time from treatment to conception. Outcomes included major congenital malformations, spontaneous abortion, preterm birth, and low birth weight. Adjusted odds ratios (aORs) were estimated using generalized estimating equations.
resultsThe study included 711 cases: 38 conceived within 1-3 months, 111 within 3-6 months, and 562 after >6 months. Major congenital malformations were diagnosed in 70 infants, with no significant difference between groups. Although numerically higher rates of congenital malformations associated with methotrexate embryopathy, preterm birth, and low birth weight were observed in the 1-3 months group, these differences were not statistically significant. Adjusted ORs for congenital malformations were 0.87 (95% confidence interval [CI]: 0.245-3.14) for 1-3 months and 1.01 (95% CI: 0.48-2.13) for 3-6 months, compared to >6 months.
conclusionConception 1-3 and 3-6 months after methotrexate treatment for ectopic pregnancy does not appear to increase the risk of major fetal malformations, or other unfavorable obstetric outcomes. Prospective studies in larger cohorts are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.